ATE444073T1 - Oxalate-abbauende mikroorganismen oder oxalate- abbauende enzyme zur verhütung der oxalate- verwandten krankheiten - Google Patents

Oxalate-abbauende mikroorganismen oder oxalate- abbauende enzyme zur verhütung der oxalate- verwandten krankheiten

Info

Publication number
ATE444073T1
ATE444073T1 AT98923673T AT98923673T ATE444073T1 AT E444073 T1 ATE444073 T1 AT E444073T1 AT 98923673 T AT98923673 T AT 98923673T AT 98923673 T AT98923673 T AT 98923673T AT E444073 T1 ATE444073 T1 AT E444073T1
Authority
AT
Austria
Prior art keywords
oxalate
degrading
preventing
related diseases
bacteria
Prior art date
Application number
AT98923673T
Other languages
English (en)
Inventor
Milton Allison
Harmeet Sidhu
Original Assignee
Oxthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxthera Inc filed Critical Oxthera Inc
Application granted granted Critical
Publication of ATE444073T1 publication Critical patent/ATE444073T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98923673T 1997-05-23 1998-05-22 Oxalate-abbauende mikroorganismen oder oxalate- abbauende enzyme zur verhütung der oxalate- verwandten krankheiten ATE444073T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4747397P 1997-05-23 1997-05-23
PCT/US1998/010495 WO1998052586A1 (en) 1997-05-23 1998-05-22 Oxalate-degrading microorganisms or oxalate-degrading enzymes for preventing oxalate related disease

Publications (1)

Publication Number Publication Date
ATE444073T1 true ATE444073T1 (de) 2009-10-15

Family

ID=21949193

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98923673T ATE444073T1 (de) 1997-05-23 1998-05-22 Oxalate-abbauende mikroorganismen oder oxalate- abbauende enzyme zur verhütung der oxalate- verwandten krankheiten

Country Status (12)

Country Link
US (1) US6200562B1 (de)
EP (2) EP2033651A1 (de)
JP (2) JP4996780B2 (de)
KR (1) KR20010012845A (de)
AT (1) ATE444073T1 (de)
AU (1) AU7590798A (de)
CA (1) CA2288709C (de)
CY (1) CY1109695T1 (de)
DE (1) DE69841200D1 (de)
ES (1) ES2334409T3 (de)
PT (1) PT983076E (de)
WO (1) WO1998052586A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US20040120941A1 (en) * 1997-05-23 2004-06-24 Allison Milton J. Materials and methods for treating or preventing oxalate-related disease
IT1309427B1 (it) 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
ATE499943T1 (de) 2001-04-23 2011-03-15 Shire Int Licensing Bv Verwendung von lanthankarbonat zur prävention von nierensteinleiden
WO2003042380A2 (en) * 2001-10-05 2003-05-22 Ixion Biotechnology, Inc. Materials and methods for reducing oxalate concentrations in fluids
US6929940B1 (en) 2002-08-20 2005-08-16 University Of Florida Research Foundation, Inc. Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use
EP1755655A4 (de) * 2004-05-07 2011-03-30 Oxthera Inc Verfahren und zusammensetzungen zum reduzieren von oxalatkonzentrationen
WO2006047680A2 (en) * 2004-10-27 2006-05-04 North Carolina State University Lactobacillus acidophilus nucleic acids and uses thereof
EP2465579A1 (de) 2005-06-10 2012-06-20 Althea Technologies, Inc. Verfahren zur Reduzierung der Oxalat-Konzentration durch Verabreichung von Oxalat-Oxidase-Kristallen
PL1962873T3 (pl) * 2005-12-14 2014-03-31 Oxthera Intellectual Property Ab Kompozycje farmaceutyczne zawierające bakterie zmniejszające ilość szczawianu
ATE499111T1 (de) * 2005-12-16 2011-03-15 Oxthera Inc Zusammensetzungen und verfahren zur oxalatreduktion
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
WO2011066282A2 (en) 2009-11-25 2011-06-03 Captozyme, Llc Methods and compositions for treating oxalate-related conditions
WO2015002588A1 (en) 2013-07-05 2015-01-08 Oxthera Intellectual Property Ab Secretagogues derived from oxalobacter formigenes
EP3078636A1 (de) 2013-12-03 2016-10-12 Kyowa Chemical Industry Co., Ltd Magnetisches hydrotalcitkomposit und verfahren zur herstellung davon
KR20180044225A (ko) 2015-04-02 2018-05-02 캡토자임, 엘엘씨 불용성 및 가용성의 옥살레이트의 분해를 위한 고효율의 옥살레이트 분해 효소
JP7016353B2 (ja) 2016-06-13 2022-02-04 オクセラ・インテレクチュアル・プロパティ・アクチボラグ オキサレート関連障害を処置または防止するための組成物および方法
US10927402B2 (en) 2018-04-10 2021-02-23 Stem Arts Projects, Llc Capsule for lyophilized reagent storage and delivery
EP3836949A4 (de) * 2018-07-18 2022-03-09 The University of Chicago Zusammensetzungen mit sel1-abgeleiteten peptiden und verfahren zur behandlung/prävention von zu hohen oxalatspiegeln und damit einhergehenden erkrankungen
WO2022140538A1 (en) * 2020-12-23 2022-06-30 Massachusetts Institute Of Technology Modified bacterium for oxalate degradation and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747397A (en) 1986-06-12 1988-05-31 Magovern George J Flexible pad for direct myocardial tissue massage having thumb loop
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
AU677976B2 (en) * 1992-11-30 1997-05-15 Syngenta Limited Oxalate decarboxylase
EP0764204B1 (de) * 1994-05-18 2001-08-22 Human Genome Sciences, Inc. HUMANE OXALYL-CoA DECARBOXYLASE
US6090628A (en) 1994-06-20 2000-07-18 University Of Florida Materials and methods for detection of Oxalobactor formigenes
US5604111A (en) 1994-06-20 1997-02-18 University Of Florida Research Foundation Method and kit for detection of oxalate

Also Published As

Publication number Publication date
EP2033651A1 (de) 2009-03-11
JP2011063597A (ja) 2011-03-31
EP0983076B1 (de) 2009-09-30
CY1109695T1 (el) 2014-08-13
KR20010012845A (ko) 2001-02-26
AU7590798A (en) 1998-12-11
JP2001526690A (ja) 2001-12-18
US6200562B1 (en) 2001-03-13
WO1998052586A1 (en) 1998-11-26
JP4996780B2 (ja) 2012-08-08
CA2288709A1 (en) 1998-11-26
CA2288709C (en) 2010-05-18
EP0983076A1 (de) 2000-03-08
DE69841200D1 (de) 2009-11-12
PT983076E (pt) 2010-01-05
ES2334409T3 (es) 2010-03-09

Similar Documents

Publication Publication Date Title
CY1109695T1 (el) Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
WO2002058684A3 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
IL208330A0 (en) 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors ('statin drugs') and lisinopril, formulations comprising them and their use in the manufacture of medicaments and as medicaments for improving nerve conduction velocity or nerve blood flow in a non-human animal having diabetic neuropathy and for treating diabetic neuropathy in a non-human animal
BRPI0015533B8 (pt) enzima alfa-l-iduronidase humana recombinante, composição farmacêutica compreendendo a mesma e método para sua purificação
DE69905368D1 (en) Oxydiertes thymosin beta 4
FI920206A0 (fi) Medicinsk anvaendning, medicinskt foerfarande och preparat.
DE69620727T2 (de) Paclitaxel Prodrogen, Verfahren zur Herstellung und ihre Verwendung zur selektiven Chemotherapie
AU8296987A (en) Pharmaceutical composition comprising fluticasone propionate
MY124714A (en) Enzyme treatment
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
ATE344664T1 (de) Verbesserte methode zur eradikation von helicobacter pylori
WO2005056520A8 (en) Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy
SE9700244D0 (sv) Novel antibacterial protein
IL112668A0 (en) 4-amino 6-substituted mycophenolic acid and derivatives thereof, their preparation and pharmaceutical compositions containing them
WO2000063348A3 (fr) Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
IL112666A0 (en) 4-amino derivatives of 5-substituted mycophenolic acid, their preparation and pharmaceutical compositions containing them
EP1083927A4 (de) Menschliches "minor vault" protein p193
DK1212072T3 (da) Farmaceutisk præparat omfattende eukalyptus- og orangeolie
SE9802836L (sv) Läkemedel för behandling av schizofreni

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0983076

Country of ref document: EP